オプションチェーンは、Valnevaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Valnevaの市場センチメントを評価します。.

Valneva (NASDAQ:VALN) 株価情報, オプションチェーン

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Valneva SE

Jefferies analyst Joe Dickstein initiates coverage on American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Buy rating and announces Price Target of $37.

News

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On American Healthcare REIT with Buy Rating, Announces Price Target of $37

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building and leading the company's 50-country operating platform. As part of this planned transition, Dr. Backstrom will serve as a strategic advisor, working closely with the company's executive team and Board of Directors.
Scholar Rock also announced today the addition of three leaders with unparalleled experience and success in building global organizations focused on developing and commercializing life-changing therapies.
<ul>
<li>Akshay Vaishnaw, M.D., Ph.D., has been named President of R&amp;D; he was formerly President of Alnylam.</li>
<li>R. Keith Woods has been appointed Chief Operating Officer and will focus on evolving the organization into a fully integrated global enterprise; he was formerly COO of argenx.</li>
<li>Vikas Sinha is joining as Chief Financial Officer; he was formerly CFO of Alexion and ElevateBio.</li>
</ul>
"On behalf of the Board, we are deeply grateful to Jay for his leadership over the past three years - driving us through the highly successful apitegromab global Phase 3 program and now into the US and European regulatory processes for marketing authorization," said Mr. Hallal. "As Board Chair, I have been continuously collaborating with Jay to accelerate Scholar Rock's evolution into a global biotech leader. These efforts will be amplified by the immediate addition of Akshay, Keith and Vikas - three operators that have built and led some of the most successful biotech companies in our industry. Together, we are committed to realizing Scholar Rock's global ambitions to bring apitegromab to SMA patients around the world."
"It has been an honor to lead the incredible team at Scholar Rock over the past several years. I am very proud of all we have achieved - from advancing apitegromab through a successful, pivotal Phase 3 study and on the path to becoming a commercial company," said Dr. Backstrom. "With the BLA now accepted under priority review and the anticipated launch later this year, this is the right moment for our leadership transition. I'm grateful for the close partnership over the years with David and Akshay as board members, and I look forward to continuing our collaboration on behalf of the SMA community to bring our highly innovative apitegromab, the world's first muscle targeted treatment, to patients and families living with the impact of this severe and progressive disease."

Management

SRRK

Scholar Rock Names Vikas Sinha as CFO, Keith Woods as COO Amid Big Biotech Expansion Plans

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported quarterly earnings of $4.78 per share which beat the analyst consensus estimate of $4.74 by 0.84 percent. This is a 8.39 percent increase over earnings of $4.41 per share from the same period last year. The company reported quarterly sales of $1.88 billion which beat the analyst consensus estimate of $1.82 billion by 3.20 percent. This is a 12.02 percent increase over sales of $1.68 billion the same period last year.

Earnings

Earnings Beats

Roper Techs Q1 Adj. EPS $4.78 Beats $4.74 Estimate, Sales $1.88B Beat $1.82B Estimate

Canaccord Genuity analyst Edward Nash initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announces Price Target of $64.

CLDX

Canaccord Genuity Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $64

As trade tensions between the U.S. and China escalate, Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) may hold a critical advantage over rival Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) through its <a href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth">diversified global manufacturing network</a>.
What Happened: While smartphones are currently exempt from President Donald Trump&#8216;s reciprocal tariffs, which reached 145% on Chinese imports this month, analysts warn that additional semiconductor-specific tariffs are forthcoming, CNN <a href="https://edition.cnn.com/2025/04/22/tech/apple-samsung-iphone-china-trade-war/index.html">reported</a>. This disparity in manufacturing footprints could prove consequential.
Apple remains heavily dependent on China, with Wedbush Securities estimating 90% of iPhone production still occurs there despite some shifts to India. By contrast, Samsung closed its last phone factory in China in 2019, with approximately 90% of its smartphone production now based in Vietnam, according to Counterpoint Research.
&#8220;The advantage is, yes, that they&#8217;re not facing the whatever crazy number we are currently dealing with,&#8221; said Gerrit Schneemann, senior analyst for Counterpoint Research.
However, analysts remain skeptical this will translate to immediate market gains for Samsung. Tight <a href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth">brand loyalty among Apple users</a> and different market positioning — Samsung dominates lower-priced segments while Apple controls premium markets — could limit customer migration.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45031324/bitcoin-ethereum-dogecoin-drop-as-stock-futures-slide-willy-woo-says-all-dips-are-for-buying-with-btc-eyeing-all-time-highs">Bitcoin, Ethereum, Dogecoin Drop As Stock Futures Slide: Willy Woo Says &#8216;All Dips Are For Buying&#8217; With BTC Eyeing &#8216;All-Time Highs</a>
Why It Matters: Additionally, <a href="https://www.benzinga.com/25/04/45032214/analyst-questions-apples-reported-iphone-shift-to-india-amid-china-tariff-pressures-doesnt-solve-all-the-problems">Vietnam and India still face 10% tariffs under Trump&#8217;s plan</a>, meaning Samsung isn&#8217;t completely insulated from trade pressures.
The broader economic impact of tariffs also threatens consumer spending on electronics. &#8220;Daily necessities and essentials are going to be higher on the list then maybe a new or upgraded smartphone,&#8221; Schneemann noted.
Apple&#8217;s potential response includes accelerating its manufacturing shift to India, though analyst Craig Moffett of MoffettNathanson questions this strategy&#8217;s effectiveness since many components would still originate from China.
UBS analysts previously estimated an iPhone assembled in China could see price increases of up to $800 before smartphone <a href="https://www.benzinga.com/25/04/44973883/analysts-slash-aapl-stock-price-target-amid-anticipated-tariffs-supply-chain-concerns-a-lose-lose-choice">exemptions were announced</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Chamath Palihapitiya Says Nvidia Is Huawei&#8217;s &#8216;New Target&#8217; — A &#8216;National Champion&#8217; That Crushed Tech Giants With A &#8216;Low-End Disruptor&#8217; Strategy</a></li>
</ul>
Image Via Shutterstock

Equities

Markets

Tech

AAPL

SSNLF

As Tariffs Bite Apple, Samsung's Global Manufacturing Network Gains Edge In US-China Trade War

- NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –
DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton's proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026.

ETON

Eton Pharma Submits NDA To FDA For Proprietary Desmopressin Oral Solution ET-600; Anticipates Q1 2026 Launch After 10-month Review

Scholar Rock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srrk#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David
Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building and leading the company's 50-country operating platform. As part of this planned transition, Dr. Backstrom will serve as a strategic advisor, working closely with the company's executive team and Board of Directors. Scholar Rock also announced today the addition of three leaders with unparalleled experience and success in building global organizations focused on developing and commercializing life-changing therapies. Akshay Vaishnaw, M.D., Ph.D., has been named President of R&amp;D; he was formerly President of Alnylam. R. Keith Woods has been appointed Chief Operating Officer and will focus on evolving the organization into a fully integrated global enterprise; he was formerly COO of argenx. Vikas Sinha is joining as Chief Financial Officer; he was formerly CFO of Alexion and ElevateBio. "On behalf of the Board, we are deeply grateful to Jay for his leadership over the past three years - driving us through the highly successful apitegromab global Phase 3 program and now into the US and European regulatory processes for marketing authorization," said Mr. Hallal. "As Board Chair, I have been continuously collaborating with Jay to accelerate Scholar Rock's evolution into a global biotech leader. These efforts will be amplified by the immediate addition of Akshay, Keith and Vikas - three operators that have built and led some of the most successful biotech companies in our industry. Together, we are committed to realizing Scholar Rock's global ambitions to bring apitegromab to SMA patients around the world." "It has been an honor to lead the incredible team at Scholar Rock over the past several years. I am very proud of all we have achieved - from advancing apitegromab through a successful, pivotal Phase 3 study and on the path to becoming a commercial company," said Dr. Backstrom. "With the BLA now accepted under priority review and the anticipated launch later this year, this is the right moment for our leadership transition. I'm grateful for the close partnership over the years with David and Akshay as board members, and I look forward to continuing our collaboration on behalf of the SMA community to bring our highly innovative apitegromab, the world's first muscle targeted treatment, to patients and families living with the impact of this severe and progressive disease."

Scholar Rock Names Chair David Hallal as New CEO Taking Over From Jay Backstrom

BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent. This is a 21.88 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $255.41 million which missed the analyst consensus estimate of $263.57 million by 3.10 percent. This is a 5.66 percent increase over sales of $241.73 million the same period last year.

Earnings Misses

BankUnited Q1 EPS $0.78 Beats $0.74 Estimate, Sales $255.41M Miss $263.57M Estimate

Chardan Capital analyst James McIlree reinstates VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) with a Buy and lowers the price target from $13 to $5.5.

Chardan Capital Reinstates Buy on VinFast Auto, Lowers Price Target to $5.5

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (SMIs) in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models. The results from these preclinical studies were shared in a poster presentation at the 2025 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois.
Key findings from the studies included:
<ul>
<li>ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), induced significantly greater tumor growth inhibition compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination.</li>
<li>ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin) resulted in tumor regressions and demonstrated significantly stronger tumor growth inhibition compared with each agent alone.</li>
<li>In preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression.</li>
<li>ARV-393 in combination with investigational small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior tumor growth inhibition compared with each agent alone, with tumor regressions in all mice treated with the combinations.</li>
</ul>

ARVN

Arvinas Reports Preclinical Results for New Lymphoma Drug Combo at Cancer Research Meeting

Telsey Advisory Group analyst Dana Telsey maintains ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) with a Outperform and raises the price target from $3 to $6.

TDUP

Telsey Advisory Group Maintains Outperform on ThredUp, Raises Price Target to $6

U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies.
The markets are jittery ahead of a packed earnings week, with four of the &#8220;Mag 7&#8221; — Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — alongside several other heavy-hitters, set to release their results over the next few days.
Investors will be closely watching the results of Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>), Domino&#8217;s Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), and NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) on Monday to set the tone for the rest of this week.
U.S. 10-Year Treasuries are at 4.26%, while the 2-Year Treasuries are at 3.77%. The CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows the markets pricing a 93.1% likelihood of interest rates remaining unchanged during the FOMC meeting, the first week of May, marking a decline from Friday, at 95.3%.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Futures</td>
<td class="has-text-align-center" data-align="center">Change (+/-)</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">-0.03%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">-0.13%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq 100</td>
<td class="has-text-align-center" data-align="center">-0.11%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">-0.32%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100 index, are both down 0.27% and 0.28% in Monday&#8217;s pre-market trading, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;138z7gr&#x2A;_gcl_au&#x2A;MjA5Njc0MjY1My4xNzQwODM2NTUw&#x2A;_ga&#x2A;R1MxLjEuMTc0NDY0ODA3Mi4yLjAuMTc0NDY0ODA3NS4wLjAuMA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTgyOTMzMy4xLjEuMTc0NTgyOTYyMy4wLjAuMA..">Benzinga Pro</a> data.
Cues From Last Week:
The markets were aided by strong earnings performances by AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), but disappointing performances by Aon PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) and HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) weighed on the rally. 
Consumer Sentiment Report (Final), released on Friday, highlighted an 8% slip in sentiments compared to the prior month, as uncertainties continue to persist, having an impact on consumer purchasing decisions.
The S&amp;P 500 capped off the week on a high note on Friday, led by communications, consumer discretionary, healthcare, and technology. Financials, consumer staples, real estate, and materials were, however, in the red during the day.
As of Friday, the Nasdaq 100 is down 12.5% from its high of 22,222.61 points, the S&amp;P 500 is down 10.1% from 6147.43 points, and the Dow Jones Industrial Average is down 11% from 45,073.63 points.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Index</td>
<td class="has-text-align-center" data-align="center">Performance (+/-)</td>
<td class="has-text-align-center" data-align="center">Value</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq Composite</td>
<td class="has-text-align-center" data-align="center">1.26%</td>
<td class="has-text-align-center" data-align="center">17,382.94</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">0.74%</td>
<td class="has-text-align-center" data-align="center">5,525.21</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">0.05%</td>
<td class="has-text-align-center" data-align="center">40,113.50</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">0.00014%</td>
<td class="has-text-align-center" data-align="center">1,957.62</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Analysts are rather upbeat going into this earnings week, with several leading experts pointing towards optimistic consensus estimates as a sign that the markets are yet to price in a recession or even a slowdown, for that matter, according <a href="https://www.ft.com/content/4aa1d7d7-4162-4e25-a6d6-a174a9626681">to</a> a report by FT. 
According to Daniel Von Ahlen of TS Lombard, &#8220;The information derived from risk assets doesn't even suggest markets reckon a mild slowdown will take shape this year.&#8221;
Peter Berezin, a chief global strategist at BCA Research, says that &#8220;typically earnings estimates decline during even mild recessions,&#8221; but the markets are now pricing a 10% earnings growth over the next twelve months, and that&#8217;s of &#8220;last year's peak profit margins no less,&#8221; he says.
See Also: <a href="https://www.benzinga.com/general/25/04/45004194/dave-ramsey-calls-social-security-a-4-return-but-this-wealth-expert-says-thats-a-dangerous-oversimplification-that-could-cost-thousands" target="_blank" rel="noreferrer noopener">Dave Ramsey Calls Social Security A ‘-4% Return' —But This Wealth Expert Says That's A Dangerous Oversimplification That Could Cost Thousands</a>
Upcoming Economic Data: 
There is no major economic data being released on Monday.
Stocks In Focus:
<ul>
<li>Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is set to release its earnings after the markets close on Monday, and the stock is up 2% in pre-market trade, with analysts expecting $2.4 billion in revenue. </li>
<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is up 0.41% in pre-market trade, as investors await its quarterly earnings release. Analysts expect $6.1 billion in revenue and $1.59 per share in earnings. </li>
<li>Cadence Design Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is largely flat pre-market, up by just 0.03%, with the company set to announce its earnings after markets close on Monday. Analysts expect $1.2 billion in revenue and earnings per share of $1.50. </li>
<li>Roper Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is an industrial conglomerate that is scheduled to announce its first quarter results before the opening bell. Consensus estimates expect $1.9 billion in revenue and $4.74 per share in earnings. </li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is up 0.59% pre-market and is set to announce its earnings after markets close. Analysts expect $2.8 billion in revenue and $2.18 per share in earnings.</li>
</ul>
Commodities, Gold And Global Equity Markets
Crude oil futures are trading down 0.46% during the early New York session, at $62.73 per barrel.
Gold Spot U.S. Dollar continued its decline, and is down 1.72% on Monday, trading at 3,275.24 per ounce, down from its record high of $3.400 per ounce last week. The U.S. Dollar Index (DXY) is up 0.03%, trading at 99.626.
Asian markets were mixed on Monday, with Japan&#8217;s Nikkei 225 Index ending up 0.38%, South Korea&#8217;s Kospi up 0.10%, followed by Indian, Australian, and New Zealand indexes edging up, with the only laggards being China&#8217;s Shanghai and Shenzhen. European markets are all up in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44942921/national-social-security-month-returns-under-trump-as-ssa-cites-1-billion-in-savings-and-vows-to-serve-the-people-by-ending-dei-contracts-and-replacing-bureaucracy-with-customer-service" target="_blank" rel="noreferrer noopener">National Social Security Month Returns Under Trump As SSA Cites $1 Billion In Savings, Vows To ‘Serve The People'</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Futures

ABBV

AMZN

CDNS

MSFT

NXPI

WELL

US Stock Futures Fall As Markets Brace For Earnings From Microsoft, Meta, Apple And Apple This Week: 'Earnings Estimates Don't Signal A Recession' Says Leading Analyst

Hyatt Hotels Corporation ("Hyatt" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>), a leading global hospitalitycompany, announced today that HI Holdings Playa B.V., an indirect wholly owned subsidiary of Hyatt ("Buyer"), has extended the offering period of its previously announced cash tender offer to purchase all of the outstanding ordinary shares of Playa Hotels &amp; Resorts N.V. ("Playa") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) for $13.50 per share in cash, less any applicable withholding taxes and without interest. The offer is being made pursuant to the previously announced purchase agreement, dated February 9, 2025 (the "Purchase Agreement"), among Hyatt, Buyer and Playa.
The tender offer is now scheduled to expire at 5:00 p.m., New York City time, on May 23, 2025, unless the tender offer is further extended or earlier terminated in accordance with the Purchase Agreement. The tender offer will continue to be extended until all conditions are satisfied or waived, or until the tender offer is terminated, in either case pursuant to the terms of the Purchase Agreement and as described in the Schedule TO filed by Hyatt and Buyer with the U.S. Securities and Exchange Commission on February 24, 2025, as amended and supplemented. Completion of the tender offer remains subject to the conditions described in the tender offer statement on Schedule TO.
For purposes of the minimum tender condition, the 83,491,904 Playa ordinary shares (excluding 2,425,261 Playa ordinary shares tendered pursuant to guaranteed delivery procedures) reported to us by Computershare Trust Company, N.A., the depositary for the tender offer, as validly tendered and not properly withdrawn as of 5:00 p.m., New York City time, on April 25, 2025, the last business day prior to the announcement of the extension of the offer, together with the 12,143,621 Shares owned by Buyer as of April 25, 2025, represents approximately 75% of the outstanding Shares (or approximately 77% including the guaranteed delivery shares). Shareholders who have already tendered their Playa ordinary shares do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the tender offer.
 &nbsp;
 &nbsp;

PLYA

Hyatt Hotels: Hi Holdings Playa Extends Cash Tender Offer Period For Playa Hotels & Resorts At $13.50/Shr In Cash

Telsey Advisory Group analyst Joseph Feldman maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Outperform and maintains $115 price target.

Telsey Advisory Group Maintains Outperform on Floor & Decor Hldgs, Maintains $115 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

Azimut Exploration Inc. ("Azimut" or the "Company") (TSXV:&nbsp;AZM) (OTCQX:&nbsp;AZMTF) is pleased to announce that it has entered into a subscription agreement with Centerra Gold Inc. ("Centerra") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CG#TSX">CG</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGAU#NYSE">CGAU</a>) for a non-brokered private placement of 9,430,000 common shares of the Company at a price of $0.60 per share for gross proceeds of $5,658,000 (the "Offering"). Centerra will become a strategic investor in the Company, acquiring approximately 9.9% of the issued and outstanding common shares following completion of the Offering.
Centerra's investment supports Azimut's strategy to create value through greenfield discoveries in Québec, Canada. The Company has demonstrated its ability to generate and advance quality targets for precious metals and critical minerals. Following the closing of the Offering, Azimut will be in a strong position to expand its exploration activities on its wholly owned Wabamisk (gold-antimony) and Elmer (gold-copper) properties. The proceeds from this Offering will be used for conducting exploration work on the Company's 100%-owned properties (including Elmer and Wabamisk), and for business development and general corporate purposes. Together with the partner-funded exploration planned for the Kukamas (nickel-copper-platinum-palladium), a significant level of activity is expected over the next 12 months. Refundable tax credits ranging from 22.5% to 45% are anticipated to be recovered on qualified exploration expenditures incurred by the Company.

CGAU

TSX:CG

Centerra Gold Takes 9.9% Stake in Azimut For $5.7M to Back New Gold and Critical Minerals Projects

Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) affirms FY2025 sales outlook from $68.03 million-$68.93 million to $68.03 million-$68.93 million vs $68.48 million estimate.

Guidance

PERF

Perfect Affirms FY2025 Sales Guidance of $68.03M-$68.93M vs $68.48M Est

Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $16.01 million which missed the analyst consensus estimate of $16.16 million by 0.90 percent. This is a 12.07 percent increase over sales of $14.29 million the same period last year.

Perfect Q1 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $16.01M Miss $16.16M Estimate

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $14 price target.

COYA

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.10 by 20 percent. This is a 50 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $3.65 billion which missed the analyst consensus estimate of $3.80 billion by 4.08 percent. This is a 7.43 percent decrease over sales of $3.94 billion the same period last year.

Comments

Valneva

Valneva (VALN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル